Related references
Note: Only part of the references are listed.Pharmacogenomics: current status and future perspectives
Munir Pirmohamed
NATURE REVIEWS GENETICS (2023)
PharmVar GeneFocus: CYP2C19
Mariana R. Botton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C9andHLA-BGenotypes and Phenytoin Dosing: 2020 Update
Jason H. Karnes et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016
Eric H. Young et al.
PLOS ONE (2021)
PharmVar GeneFocus: CYP2C19
Mariana R. Botton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI Results of the GIANT Study
Jean-Sebastien Hulot et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2020)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs
Katherine N. Theken et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
2020 American College of Rheumatology Guideline for the Management of Gout
John D. FitzGerald et al.
ARTHRITIS & RHEUMATOLOGY (2020)
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Christopher Taylor et al.
GENES (2020)
The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review
Don Roosan et al.
PHARMACOGENOMICS (2020)
Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation
Aleksi Tornio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy
Rossana Roncato et al.
GENES (2019)
Genetic variants and interactions from a pharmacist-led pharmacogenomics service for PACE
Kevin T. Bain et al.
PHARMACOGENOMICS (2019)
Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients
Miguel A. Gomez-Bravo et al.
PHARMACOGENETICS AND GENOMICS (2018)
Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project
Kathrin Blagec et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2018)
Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype
Nuria Lloberas et al.
PHARMACOGENOMICS (2018)
Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula
Francesco Carano et al.
ANNALS OF HUMAN BIOLOGY (2018)
Multidisciplinary model to implement pharmacogenomics at the point of care
Pedro J. Caraballo et al.
GENETICS IN MEDICINE (2017)
Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration - experience from a pediatric tertiary care facility
Shannon F. Manzi et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2017)
Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults
J. T. Hanlon et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Common Drug Side Effects and Drug-Drug Interactions in Elderly Adults in Primary Care
Susan E. Merel et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2017)
Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
Muh Akbar Bahar et al.
PHARMACOGENOMICS (2017)
What is polypharmacy? A systematic review of definitions
Nashwa Masnoon et al.
BMC GERIATRICS (2017)
Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial
Lindsay S. Elliott et al.
PLOS ONE (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron
G. C. Bell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Integrating clinical decision support systems for pharmacogenomic testing into clinical routine - a scoping review of designs of user-system interactions in recent system development
Marc Hinderer et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2017)
Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing
Brian Thomas Hocum et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy
D. Brixner et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Disease-Drug Database for Pharmacogenomic-Based Prescribing
S. Hussain et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alerts
Adam A. Nishimura et al.
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS (2016)
Preemptive Pharmacogenomic Testing for Precision Medicine A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade
Yuan Ji et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease
Roseann S. Gammal et al.
PEDIATRICS (2016)
CYP3A4 intronic SNP rs35599367 (CYP3A4☆22) alters RNA splicing
Danxin Wang et al.
PHARMACOGENETICS AND GENOMICS (2016)
Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study
Kathrin Blagec et al.
PEERJ (2016)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
J. K. Hicks et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing
Adam A. Nishimura et al.
GENETICS IN MEDICINE (2015)
Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians
Casey Lynnette Overby et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2015)
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes
C. A. Altar et al.
PHARMACOGENOMICS JOURNAL (2015)
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
M. Apellaniz-Ruiz et al.
PHARMACOGENOMICS JOURNAL (2015)
Clinical pharmacogenetics implementation: Approaches, successes, and challenges
Kristin W. Weitzel et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2014)
PG4KDS: A model for the clinical implementation of pre-emptive pharmacogenetics
James M. Hoffman et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2014)
Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: A mixed methods approach
Emily Beth Devine et al.
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS (2014)
Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time-Using Genomic Data to Individualize Treatment Protocol
Suzette J. Bielinski et al.
MAYO CLINIC PROCEEDINGS (2014)
An Ontology-Based, Mobile-Optimized System for Pharmacogenomic Decision Support at the Point-of-Care
Jose Antonio Minarro-Gimenez et al.
PLOS ONE (2014)
Cleveland Clinic's Center for Personalized Healthcare: setting the stage for value-based care
Kathryn Teng et al.
PHARMACOGENOMICS (2014)
How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping
Paul Verbeurgt et al.
PHARMACOGENOMICS (2014)
Understanding and preventing drug-drug and drug-gene interactions
Cara Tannenbaum et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2014)
The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics-Pharmacogenomics
O. Gottesman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Electronic health record design and implementation for pharmacogenomics: a local perspective
Josh F. Peterson et al.
GENETICS IN MEDICINE (2013)
Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model
Cristina Mazzaccara et al.
PLOS ONE (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Medication reviews
Alison Blenkinsopp et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project
J. M. Pulley et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics
P. H. O'Donnell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
A Review of Pharmacogenetics of Adverse Drug Reactions in Elderly People
Maurizio Cardelli et al.
DRUG SAFETY (2012)
Inappropriate Prescribing of Proton Pump Inhibitors in Older Patients
Hanifat Hamzat et al.
DRUGS & AGING (2012)
The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation
P. Stratta et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population
Z-L Dong et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2012)
Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug - Drug Interactions
Maria Karlgren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Developing a Prototype System for Integrating Pharmacogenomics Findings into Clinical Practice
Casey Lynnette Overby et al.
JOURNAL OF PERSONALIZED MEDICINE (2012)
Association Between CYP3A5 Polymorphisms and Blood Pressure in Kidney Transplant Recipients Receiving Calcineurin Inhibitors
Mariano Ferraresso et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2011)
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Laura Magliulo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly
L. Pasina et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2011)
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study
Laure Elens et al.
PHARMACOGENETICS AND GENOMICS (2011)
Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial
D. Serrano et al.
PHARMACOGENOMICS JOURNAL (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Pharmacogenetics of cytochrome P450 (CYP) in the elderly
Davide Seripa et al.
AGEING RESEARCH REVIEWS (2010)
PharmGKB very important pharmacogene: SLCO1B1
Connie Oshiro et al.
PHARMACOGENETICS AND GENOMICS (2010)
Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes
Chiara De Luca et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin
Yuan Gao et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The relationship between number of drugs and potential drug-drug interactions in the elderly - A study of over 600 000 elderly patients from the Swedish prescribed drug register
Kristina Johnell et al.
DRUG SAFETY (2007)
Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation
Yong-Fang Hu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
A Westlind-Johnsson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Overriding of drug safety alerts in computerized physician order entry
H Van der Sijs et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2006)
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Significance of the minor cytochrome P450 3A isoforms
AK Daly
CLINICAL PHARMACOKINETICS (2006)
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population
MG Scordo et al.
PHARMACOLOGICAL RESEARCH (2004)
Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients
M Spreafico et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2003)